Counterpoint Mutual Funds LLC Purchases Shares of 20,547 Ralliant Corporation $RAL

Counterpoint Mutual Funds LLC purchased a new position in shares of Ralliant Corporation (NYSE:RAL) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 20,547 shares of the company’s stock, valued at approximately $855,000.

Other hedge funds have also recently made changes to their positions in the company. Danske Bank A S bought a new position in shares of Ralliant during the 4th quarter valued at $25,000. Palisade Asset Management LLC bought a new stake in Ralliant in the third quarter worth $26,000. V Square Quantitative Management LLC bought a new stake in Ralliant in the fourth quarter worth $26,000. Allworth Financial LP lifted its stake in Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. Finally, BOKF NA purchased a new stake in Ralliant during the third quarter valued at about $29,000.

Ralliant Trading Down 0.0%

NYSE RAL opened at $68.34 on Friday. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. The stock has a 50 day simple moving average of $60.61 and a two-hundred day simple moving average of $51.93. The stock has a market cap of $7.65 billion and a P/E ratio of -6.25.

Ralliant (NYSE:RAL) last posted its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. The firm had revenue of $534.60 million for the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were issued a $0.05 dividend. The ex-dividend date was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is -1.83%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on RAL. Wall Street Zen cut Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Barclays boosted their target price on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Citigroup increased their target price on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 13th. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Finally, Oppenheimer lifted their price target on Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Ralliant presently has an average rating of “Moderate Buy” and a consensus target price of $69.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.